NeuroOne Announces CFO Succession: McClurg Retires, Volker Takes Helm

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced a key leadership transition as Ron McClurg prepares to retire as Chief Financial Officer, effective June 30, 2026. McClurg, who has served as CFO for over five years, will remain with the company as a Senior Advisor through December 31, 2026, to ensure a smooth handover. Stepping into the permanent CFO role is Chris Volker, NeuroOne's current Chief Operating Officer, a CFA® charterholder with more than 25 years of operational and financial leadership in the medical device industry. Volker’s extensive background includes senior roles at Abbott, Cardiovascular Systems, Inc. (CSI), and St. Jude Medical, where he honed expertise in corporate finance, international expansion, and strategic planning. Meanwhile, David Wambeke, NeuroOne's newly appointed Chief Business Officer, will take over many of Volker's previous responsibilities, reinforcing the company's leadership depth.

The transition comes as NeuroOne continues to advance its innovative electrode technology platform, which includes four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions are designed to improve surgical outcomes for neurological disorders by reducing hospitalizations, lowering costs, and offering both diagnostic and therapeutic capabilities. The company is also actively researching drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. CEO Dave Rosa expressed gratitude for McClurg's contributions and confidence in Volker's ability to drive the company's growth strategy forward, building on the strong foundation established under McClurg's tenure.

Volker's appointment underscores NeuroOne's commitment to leveraging seasoned leadership as it scales its commercial and pipeline efforts. With his background in medtech finance and operations, Volker is poised to guide the company through its next phase of innovation and market expansion. McClurg's continued advisory role ensures continuity, while the broader leadership team remains focused on delivering cutting-edge solutions for patients with neurological disorders. For more details, visit the NEWMEDIAWIRE release.